Case Reports

Objective Soft Tissue Assessment Supports Optimal Surgical Timing When Clinical Signs Are Inconclusive
Featured

Objective Soft Tissue Assessment Supports Optimal Surgical Timing When Clinical Signs Are Inconclusive

July 9, 2026
by
Read
Recent Case Reports
Quantifiable Soft Tissue Assessment Prompted Immediate Fasciotomy When Clinical Findings Were Inconclusive

Quantifiable Soft Tissue Assessment Prompted Immediate Fasciotomy When Clinical Findings Were Inconclusive

July 9, 2026
by
Read
Compremium Quantis ST supported rapid risk stratification and OR prioritization

Compremium Quantis ST supported rapid risk stratification and OR prioritization

July 9, 2026
by
Read
Quantify Soft Tissue: Avoided Prophylactic Fasciotomy

Quantify Soft Tissue: Avoided Prophylactic Fasciotomy

July 9, 2026
by
Read
Post-traumatic swelling characterization to reduce uncertainty in ACS risk stratification and surgical decision-making

Post-traumatic swelling characterization to reduce uncertainty in ACS risk stratification and surgical decision-making

July 9, 2026
by
Read

Experience Compremium Quantis ST in Action

Compremium Quantis ST is CE-marked and FDA- Cleared.
Book your consultation
Flag of Sweden
Swiss engineered
2026 Compremium AG
Follow us on LinkedIn
Why Quantify?SolutionClinical Evidence
CompanyContact UsPrivacy PolicyData Protection
CPMX1 is now called Compremium Quantis ST